Required for US and Japanese stocks. A-shares and HK stocks work without a key.
DeepSeek R1 provides high-quality analysis at very low cost. Serper provides real-time search data for context.
Required for US and Japanese stocks. A-shares and HK stocks work without a key.
DeepSeek R1 provides high-quality analysis at very low cost. Serper provides real-time search data for context.
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.
交易所：HKG。行业板块：Healthcare。细分行业：Medical Care Facilities。最新股价：HK$2.12。本页提供 Jinxin Fertility Group Limited 的 DCF 现金流折现估值、相对估值历史分位、多维财务评分与 AI 辅助分析。